FDA Drug GMP Warning Letter Usage Remains Low In FY 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency issues 30 drug good manufacturing practices warning letters in fiscal year 2004, compared to 29 a year earlier. Sixteen of the 30 warning letters addressed stability program deficiencies, while equipment cleaning and QC unit problems appeared in half.
You may also be interested in...
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.
Otsuka Busulfex's Overall Survival Claim Does Not Survive CDER Advertising Scrutiny
Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).